JAK1 and acute lymphoblastic leukemia: In summary, our work provides the first evidence that the newly identified JAK1 S646P mutation is an activating mutation in vitro and in vivo, and highly sensitive to JAK inhibitor, encouraging studies aimed at testing the efficacy and side effects of ruxolitinib in the treatment for ALL.